A Dual Transformation: From DNA Sequencing to Crypto Treasury
In November 2025, a long-standing Nasdaq-listed firm made a dramatic pivot, shedding its identity as Applied DNA Sciences to become BNB Plus Corp. This wasn't merely a rebranding exercise but a strategic shift in core business—from biotechnology and nucleic acid production to managing digital asset treasuries, with a focus on BNB. The company's stock ticker changed to BNBX to reflect its new direction.
Strategic Shift Amid Geopolitical Pressures
This transformation followed its inclusion in a Chinese countermeasures list announced by the Ministry of Commerce in August of the same year. Facing increased external pressure, the company decided to double down on the digital asset space while maintaining, at least nominally, its legacy biotech operations. The move positioned it as a hybrid entity straddling two vastly different industries.
The Market's Verdict: A Steep Decline
Investors have been highly skeptical of this bold strategy. The company's stock performance tells a stark story: shares currently trade around $0.11, representing a collapse of more than 92% since the beginning of 2026. This catastrophic loss in market value triggered significant regulatory consequences.
Falling Foul of Listing Rules
The persistently low share price, below the critical $1 threshold, led Nasdaq to issue a delisting notice on July 13. As a result, BNB Plus was compelled to move its trading venue from the main Nasdaq exchange to the OTCQB Venture Market. This over-the-counter platform is typically associated with smaller, riskier companies and offers far less liquidity and visibility, complicating future capital-raising efforts and damaging corporate credibility.
An Uphill Battle Ahead
The story of BNB Plus highlights the profound challenges traditional firms face when venturing into the volatile cryptocurrency sector. Its attempt to bridge a stable biotech foundation with a high-risk crypto treasury model has so far failed to convince the market, resulting in a severe financial and regulatory predicament. Its journey will serve as a cautionary tale for other companies considering similar transitions.